Achillion Pharmaceut (ACHN) 8.37 $ACHN ACHN March 2017

New Post Public Reply Private Reply Replies (0) Message Board

Aug 1, 2016 at 10:18 AM

Achillion Pharmaceut (ACHN) 8.37 $ACHN

ACHN March 2017 Options Begin Trading
DividendChannel.com - Mon Jul 18, 10:24AM CDT
Investors in Achillion Pharmaceuticals Inc. saw new options become available today, for the March 2017 expiration.
ACHN: 8.37 (+0.09)

Achillion Presents Interim Phase 1 Results for ACH-4471, a Novel Orally-Administered Factor D Inhibitor, at the 21st Congress of the European Hematology Association
GlobeNewswire - Fri Jun 10, 2:30AM CDT
- Results indicate up to 100% inhibition of alternative-pathway (AP) activity in hemolysis and Wieslab assays after oral dosing of ACH-4471 -
ACHN: 8.37 (+0.09)

Biotechnology Equities Technical Notes -- Grifols, Achillion Pharma, Jazz Pharma, and Puma Biotechnology
PR Newswire - Wed Jun 08, 7:25AM CDT
On Tuesday, June 07, 2016, the NASDAQ Composite ended the trading session at 4,961.75, down 0.14%; the Dow Jones Industrial Average advanced 0.10% to finish at 17,938.28; and the S&P 500 closed at 2,112.13, up 0.13%. The gains were broad based as eight out of nine sectors ended the session in positive. ActiveWallSt.com has initiated coverage on the following equities: Grifols S.A. (NASDAQ: GRFS), Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Jazz Pharmaceuticals PLC (NASDAQ: JAZZ), and Puma Biotechnology Inc. (NYSE: PBYI). Learn more about these stocks by accessing their free trade alerts at:
ACHN: 8.37 (+0.09), JAZZ: 150.18 (-0.79), GRFS: 16.90 (-0.04), PBYI: 50.38 (+0.49)

Achillion to Present at Three Upcoming Investor Conferences
GlobeNewswire - Wed Jun 01, 3:02PM CDT
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at three upcoming investor conferences:
ACHN: 8.37 (+0.09)

Achillion Announces Acceptance of Late Breaking Abstract for ACH-4471 at the 21st Congress of the European Hematology Association
GlobeNewswire - Thu May 19, 5:05AM CDT
- Interim results, including safety, pharmacokinetics and pharmacodynamics, to be presented from ongoing phase 1 single-ascending dose trial with ACH-4471 in healthy volunteers -
ACHN: 8.37 (+0.09)

Achillion reports 1Q loss
Automated Insights - Tue May 03, 5:19AM CDT
NEW HAVEN, Conn. (AP) _ Achillion Pharmaceuticals Inc. (ACHN) on Tuesday reported a loss of $18.1 million in its first quarter.
ACHN: 8.37 (+0.09)

Achillion Reports First Quarter 2016 Financial Results and Provides Update on Clinical Programs
GlobeNewswire - Tue May 03, 5:05AM CDT
- Company provides update on HCV collaboration with Janssen; Phase 2b combination study evaluating doublet and triplet regimens for six and eight weeks anticipated to begin in Q3 2016 -
ACHN: 8.37 (+0.09)

Achillion to Present at the Deutsche Bank 41st Annual Health Care Conference
GlobeNewswire - Thu Apr 28, 5:05AM CDT
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at the Deutsche Bank 41 Annual Health Care Conference on Thursday, May 5, 2016 at 1:30 p.m. EDT at The InterContinental Hotel in Boston, MA.
ACHN: 8.37 (+0.09), DB: 13.16 (-0.28)

Can the Uptrend Continue for Achillion Pharmaceuticals (ACHN)?
Zacks Equity Research - Zacks Investment Research - Tue Apr 26, 7:02AM CDT
Investors certainly have to be happy with Achillion Pharmaceuticals, Inc. (ACHN) and its short term performance
ACHN: 8.37 (+0.09)

First Week of December 16th Options Trading For Achillion Pharmaceuticals (ACHN)
DividendChannel.com - Tue Apr 19, 9:57AM CDT
Investors in Achillion Pharmaceuticals Inc. saw new options become available this week, for the December 16th expiration.
ACHN: 8.37 (+0.09)

ObsEva Strengthens Board with Appointment of Biotechnology Veteran Dr. Frank Verwiel
GlobeNewswire - Thu Mar 24, 7:09AM CDT
ObsEva, a Swiss biopharmaceutical company innovating women's reproductive health and pregnancy therapeutics, today announced the appointment of Frank Verwiel, MD to its Board of Directors. Over the last 25 years, Dr. Verwiel has amassed a wealth of knowledge across multiple operational, development, and commercial disciplines for both small and large biotechnology and pharmaceutical companies. Most recently, Dr. Verwiel was President and Chief Executive Officer of Aptalis Pharma, Inc. (formerly Axcan Pharma Inc.), which was acquired by Forest Laboratories for $2.9 billion in 2014.
ACHN: 8.37 (+0.09), AVXS: 35.99 (-1.64)

Tuberculosis Therapeutics Development Pipeline Review, H2 2015 Featuring 60 Key Companies
M2 - Fri Feb 05, 4:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/b2fbvp/tuberculosis) has announced the addition of the "Tuberculosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Tuberculosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tuberculosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Tuberculosis Overview - Therapeutics Development - Pipeline Products for Tuberculosis - Overview - Pipeline Products for Tuberculosis - Comparative Analysis - Tuberculosis - Therapeutics under Development by Companies - Tuberculosis - Therapeutics under Investigation by Universities/Institutes - Tuberculosis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Tuberculosis - Products under Development by Companies - Tuberculosis - Products under Investigation by Universities/Institutes - Tuberculosis - Companies Involved in Therapeutics Development - Abera Bioscience AB - Achillion Pharmaceuticals, Inc. - BioDiem Ltd - BioLingus AG - Biomar Microbial Technologies - Bioversys AG - Celgene Corporation - Cellceutix Corporation - Chongqing Zhifei Biological Products Co., Ltd. - Ensol Biosciences Inc. - EpiVax, Inc. - FIT Biotech Oy - GangaGen Inc. - GlaxoSmithKline Plc - Globeimmune, Inc. - Hsiri Therapeutics, LLC - Imaxio SA - Immunitor, Inc. - ImmunoBiology Limited - Immunovaccine, Inc. - Inovio Pharmaceuticals, Inc. - Johnson & Johnson - Lipotek Pty Ltd. - Microbion Corporation - Microbiotix, Inc. - NEARMEDIC PLUS, Ltd - Novartis AG - Okklo Life Sciences BV - Orchid Chemicals & Pharmaceuticals Ltd - Otsuka Holdings Co., Ltd. - Polymun Scientific Immunbiologische Forschung GmbH - Prokarium Limited - QureTech Bio AB - Sanofi - Vichem Chemie Research Ltd. For more information visit http://www.researchandmarkets.com/research/b2...berculosis
JNJ: 125.12 (-0.11), INO: 10.26 (+0.38), ACHN: 8.37 (+0.09), GSK: 44.99 (-0.08), NVS: 82.98 (-0.28), CELGZ: 1.12 (-0.04)

Why Achillion Pharmaceuticals Shares Crashed 37% in January
Todd Campbell, The Motley Fool - Motley Fool - Thu Feb 04, 2:40PM CST
Image source: Achillion Pharmaceuticals. W hat: Despite announcing a key new hire last month, shares in the clinical-stage drugmaker Achillion Pharmaceuticals dropped 37.3% in January, according to S&P Capital IQ. So what: On Jan....
JNJ: 125.12 (-0.11), GILD: 79.70 (+0.23), ACHN: 8.37 (+0.09), BMY: 75.41 (+0.60)

Achillion Announces Appointments of Martha Manning as General Counsel and Amy Jennings as Head of Regulatory Affairs
GlobeNewswire - Wed Feb 03, 5:05AM CST
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced the addition of two members to the senior management team. Martha Manning, Esq., joins Achillion as Executive Vice President, General Counsel and Secretary effective February 1, 2016. In addition, Amy Jennings, Ph.D., recently joined the Company and will serve as Senior Vice President of Regulatory Affairs.
ACHN: 8.37 (+0.09)

Zacks.com featured expert Kevin Matras highlights: Achillion Pharmaceuticals, Opko Health, Global Eagle Entertainment, LendingClub and Barracuda Networks
Zacks Equity Research - Zacks Investment Research - Wed Jan 27, 8:30AM CST
Zacks.com featured expert Kevin Matras highlights: Achillion Pharmaceuticals, Opko Health, Global Eagle Entertainment, LendingClub and Barracuda Networks
LC: 4.59 (-0.03), OPK: 9.94 (-0.01), ACHN: 8.37 (+0.09), CUDA: 22.25 (+0.17), ENT: 8.40 (+0.20)

Paroxysmal Nocturnal Hemoglobinuria Therapeutics Pipeline Review - H2 2015 Report
M2 - Wed Jan 27, 4:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/nnv8gp/paroxysmal) has announced the addition of the "Paroxysmal Nocturnal Hemoglobinuria - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Paroxysmal Nocturnal Hemoglobinuria, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Paroxysmal Nocturnal Hemoglobinuria and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Paroxysmal Nocturnal Hemoglobinuria Overview - Therapeutics Development - Pipeline Products for Paroxysmal Nocturnal Hemoglobinuria - Overview - Pipeline Products for Paroxysmal Nocturnal Hemoglobinuria - Comparative Analysis - Paroxysmal Nocturnal Hemoglobinuria - Therapeutics under Development by Companies - Paroxysmal Nocturnal Hemoglobinuria - Therapeutics under Investigation by Universities/Institutes - Paroxysmal Nocturnal Hemoglobinuria - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Paroxysmal Nocturnal Hemoglobinuria - Products under Development by Companies - Paroxysmal Nocturnal Hemoglobinuria - Products under Investigation by Universities/Institutes - Paroxysmal Nocturnal Hemoglobinuria - Companies Involved in Therapeutics Development - Achillion Pharmaceuticals, Inc. - Alexion Pharmaceuticals, Inc. - Alnylam Pharmaceuticals, Inc. - Amyndas Pharmaceuticals LLC - Apellis Pharmaceuticals, Inc. - Epirus Biopharmaceuticals, Inc. - Novartis AG - Omeros Corporation - Ra Pharmaceuticals, Inc. - Regenesance BV - The International Biotechnology Center (IBC) Generium For more information visit http://www.researchandmarkets.com/research/nnv8gp/paroxysmal
ACHN: 8.37 (+0.09), ALXN: 132.11 (+3.51), OMER: 11.92 (+0.16), NVS: 82.98 (-0.28)

A Company's First Profit Can Mean Big Profits to Investors
Kevin Matras - Zacks Investment Research - Tue Jan 26, 2:04PM CST
A Company's First Profit Can Mean Big Profits to Investors
LC: 4.59 (-0.03), OPK: 9.94 (-0.01), ACHN: 8.37 (+0.09), CUDA: 22.25 (+0.17), ENT: 8.40 (+0.20)

The Zacks Analyst Blog Highlights: Gilead, Horizon Pharma, AVEO Pharmaceuticals, Achillion Pharmaceuticals and Inovio Pharmaceuticals
Zacks Equity Research - Zacks Investment Research - Tue Jan 12, 8:30AM CST
The Zacks Analyst Blog Highlights: Gilead, Horizon Pharma, AVEO Pharmaceuticals, Achillion Pharmaceuticals and Inovio Pharmaceuticals
INO: 10.26 (+0.38), GILD: 79.70 (+0.23), ACHN: 8.37 (+0.09), AVEO: 1.01 (+0.01), HZNP: 19.62 (+0.33)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Bob Evans' Protein Mac & Cheese: Practical Power Play

Has anyone else noticed just how fast the world spins when it comes to consumer trends these days? Bob Evans is hopping right on the protein bandwagon with its latest launch, a microwave-ready Protein Macaroni & Cheese that packs 18 grams of protein per serving. You gotta hand it to them for seizing opportunity when they see it. This one's not just about tossing a new...

Cala Launches Game-Changer Wearable for Tremor Relief

Breaking New Ground in Neuromodulation Medical tech's on a roll, and Cala Health just hopped on the fast track with their latest launch—the Cala kIQ Plus System. This bad boy is aiming to offer relief for those grappling with hand tremors, thanks to its FDA clearance and a host of new features. It's the first of its kind, combining multiple therapy modes with an...

Pushing for National Liver Cancer Awareness in 2026

The Urgency of Liver Cancer Awareness Death doesn’t wait, does it? When liver cancer is the villain in question, every moment becomes precious because this beast doesn’t roar until it’s too late. Here we are in 2026, staring at nearly 31,000 annual deaths in the U.S. alone. But hope flickers with a new congressional resolution aiming to slap a bright spotlight on...

Charter Next Generation Unveils Gen 2 MDO-PE Films

Peering Into CNG's Latest Innovation Charter Next Generation (CNG) just threw down a hefty gauntlet with its launch of next-gen machine-direction-oriented polyethylene (MDO-PE) solutions. They're pushing the envelope on what recycle-ready packaging can do, folks. Let's not mince words—other players in the field better have their game faces on. This ain't just another...

Karoo Health Leaps Forward with New CCO Breton

Change of Guard in Cardiac Health at Karoo Here's a move that might shake things up in the healthtech sector: Karoo Health just snagged Angela "Angie" Breton as their new Chief Commercial Officer. It's like putting a seasoned captain at the helm right before setting sail on uncharted waters. Breton's not just any captain—she's got a hefty 25 years of experience...

Epic Political Thriller Explores Humanity's Future

Adams' Provocative Debut Asks Timeless Questions Sometimes life throws a philosophical curveball, and that's exactly what John C. Adams has done with his debut novel, The Third Phase. This isn't your average political yarn—it's an intricate tapestry intertwining political intrigue, deep spiritual inquiry, and hearty doses of classic philosophy. A Whirlwind Journey...

Dentistry.One Achieves HITRUST i1, Boosts Cybertrust

HITRUST i1 Certification: The Gold Standard in Security For a world increasingly reliant on digital infrastructure, cybersecurity certification is no longer just a badge of honor; it's a cornerstone of trust. Dentistry.One nailed this down by bagging that coveted HITRUST i1 certification. When folks talk about securing data, HITRUST might as well be speaking gospel. We're...

Purina Institute Highlights Nutritional Science at WSAVA 2026

A Global Stage for Pet Nutrition Science The folks over at the Purina Institute are back in the spotlight as they gear up to throw their weight behind the 51st World Small Animal Veterinary Association (WSAVA) Congress in Warsaw, Poland. Set for October 13-15, 2026, this isn’t just another event—they're bringing some serious clout with their 'Food for Thought'...

Community Banks Missing $106B Lending Opportunity?

A Missed Opportunity for Community Banks It's a classic tale: community banks sleepwalking while big players snatch up low-hanging fruit right in their own backyards. According to the latest report by Cornerstone Advisors, commissioned by Teslar Software, these banks are essentially leaving $106 billion on the table when it comes to consumer lending. That's not just chump...

JiMMYBAR! Expands Creatine Market with Target Launch

JiMMYBAR! Breaks New Ground in Supplements You ever notice how some companies just know how to shake things up? Take JiMMYBAR!, for instance. The moment I read they’re making moves to get their Creatine + Protein bars into Target stores nationwide, starting October 4, I thought, “That’s one way to drag creatine out from the dusty tub and onto the shelves of...